Cargando empresa
Just reported
Q3 FY2026 results
From Citius Oncology's results release of 26 de octubre de 2026; its quarterly report has since been filed.
Revenue
Actual
1,5M US$
-10 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,08 US$
Guided
—
No guide given
Operating income, GAAP
Actual
-8,7M US$
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Citius Oncology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited33,5B US$A
NBIXNeurocrine Biosciences, Inc.17,6B US$A+
ELANElanco Animal Health Incorporated13,2B US$A
KNSAKiniksa Pharmaceuticals International, plc8,1B US$A+
LQDALiquidia Corporation5B US$A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Estados financieros completos →
Construido a partir de los propios informes de Citius Oncology, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
